Kornimate/medical-research-clean huggingface dataset:
a clinical investigation on early visible effects of application of k101 during 8 weeks on discoloured and deformed nails resulting from onychomycosis

Conditions: Onychomycosis

Summary: the purpose of this study is to further evaluate and document early visible effects on nail appearance of topical k101.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18 years or older * 25%-75% of the target nail altered as a result of onychomycosis * signed written informed consent exclusion criteria * proximal subungual onychomycosis * patient who has been previously randomized to treatment in the phase iii study k70-2 investigating k101 * other conditions known to cause abnormal nail appearance * use of topical (1 month before screening) and/or systemic (3 months before screening) antifungal medication. * participation in another clinical study with an investigational drug or device during the previous 4 weeks before enrolment. * known allergy to any of the tested treatment products

Keywords: discoloured and deformed nails resulting from onychomycosis
at-home infusion using bamlanivimab in participants with mild to moderate covid-19

Conditions: Covid19

Summary: this is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate covid-19. participants will track for developing symptoms while at home and upon reporting of symptoms will test for covid-19. if positive for covid-19, a one-time at-home infusion of bamlanivimab (ly3819253) will be provided by optum infusion. participants will then track for 28 days to assess for any additional medical care needed or if hospitalization was required.


Eligibility criteria:
inclusion criteria: * unitedhealthcare member * confirmed covid-19 positive * located in an area where bamlanivimab (ly3819253) is available for infusion exclusion criteria: * current (from first symptom report) hospitalization for covid-19 * prior administration of bamlanivimab or other covid-19 therapies * previous covid-19 diagnosis * prior receipt of a covid-19 vaccine * not authorized for patient use per the eua

Keywords: covid19 bamlanivimab unitedhealth
improving knowledge of medication in ulcerative colitis with an iphone application

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to assess an iphone application to increase adherence to maintenance medications in subjects with ulcerative colitis.

inflammatory bowel disease is a chronic condition that requires maintenance medication to maintain clinical remission. during clinical remission patient can be free of symptoms for long periods of time. inflammatory bowel disease patients have been shown to have adherence rates around 40-60%. non-adherence in patients in clinical remission is high with rates around 60%. non adherence in patients in clinical remission can have significant impact because it can lead to higher rates of clinical flares and increased health care cost. this will be a single-blinded randomized controlled trial to evaluate if patients randomized to an ipphone application vs. control can increase the adherence of their maintenance medication. the trial will last three months and we hope to enroll 99 patients. the primary outcome will be adherence measured by the medication possession ratio. the secondary objective will be to evaluate if a validated adherence questionnaire can predict adherence in patients with inflammatory bowel disease. having an intervention that can increase adherence can provide better care for patients. also having a validated survey tool can accurately identify non-adherence in inflammatory bowel disease patient would be a valuable tool for patient care.

Eligibility criteria:
inclusion criteria: * at least 18 -65 years of age. * diagnosed with ulcerative colitis established by history and biopsy confirmed by gastroenterology. * on a stable dose of mesalamine for at least two months prior to entering the study * have an iphone (personal iphone) * patient may receive steroid or mesalamine enemas during the study only on an as needed basis exclusion criteria: • are on more than one medication for their inflammatory bowel disease
chemotherapy or chemotherapy plus pd-1 antibody in ret fusion positive advanced nsclc patitnts: the poseidon trial

Conditions: Non-small Cell Lung Cancer

Summary: this study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus pd-1 antibody in ret fusion positive advanced non-small cell lung cancer.

this study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the pd-1 antibody in ret fusion positive advanced non-small cell lung cancer. we aim to enrolled 100 patients in this study, the primary endpoint was pfs.

Eligibility criteria:
inclusion criteria: * ≥18，advanced non-squamous non-small cell lung cancer confirmed by histopathology * ret fusion positive * first diagnosis and treatment * treatment plan is chemotherapy or chemotherapy plus pd-1 antibody exclusion criteria: * - patients received antitumor treatment before * patients with contraindication of chemotherapy * pregnant or breast feeding women

Keywords: pd-l1 ;ret fusion lung cancer patients
validation of fdg-pet segmentation tools for tumor delineation by correlation of ct- and fdg-pet volume measurements with histopathology of nodal metastases of head and neck carcinomas.

Conditions: Head and Neck Cancer

Summary: various methods of fdg-pet signal segmentation will be validated by correlation of histopathologically measured tumor dimensions in lymph node dissection specimens of head-and-neck cancer patients.


Eligibility criteria:
inclusion criteria: * all patients with n+ squamous cell carcinoma of the head and neck, planned for neck dissection. * age \>18 years. exclusion criteria: * pregnancy. * women breast feeding

Keywords: fdg-pet segmentation tools head-and-neck cancer histological validation
plasma dipeptidyl-peptidase-4 activities with no-reflow and bleeding

Conditions: Dipeptidyl-peptidase-4; STEMI; PCI; No-reflow; Bleeding

Summary: dipeptidyl-peptidase-4 (dpp4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (ami). however clinical data of dpp4a in ami patients is sparse. this study was to investigate the role of plasma dpp4 activity (dpp4a) in patients with st-segment elevation myocardial infarction (stemi) treated with percutaneous coronary intervention (pci). this was a analysis of consecutive patients conducted at a tertiary referral center from january 2014 to october 2015. the investigators included 747 stemi-patients, treated with pci from january 2013 to october 2015. blood samples were collected immediately at admission. the patients were divided into four groups according to dpp4a quartile.

st-segment elevation myocardial infarction (stemi) is an acute manifestation of coronary heart disease, remaining a frequent cause of death.a better understanding of risk factors and pathogenic mechanisms underlying stemi may help improve the prognosis and life quality of these patients.dipeptidyl peptidase 4 (dpp4) is an exopeptidase expressed on the surface of diverse cells, cleaving off amino-terminal dipeptides with either l-proline, l-alanine or serine at the penultimate position. as a cell surface protein, it participates in immune regulation, signal transduction and apoptosis. dpp4 also circulates as a soluble form in the plasma. soluble dpp4 came from either membrane type clearance or secreted by cells like endothelial cells, with enzymatic activity. plasma dpp4 activity (dpp4a) are elevated in several diseases, including type 2 diabetes, obesity, atherosclerosis and osteoporosis. basic studies have showed that dpp4 inhibition leads improved survival and heart function after cardiac ischemia-reperfusion (i/r) injury, and this is partly due to activation of akt (pakt), pgsk3 and anp pathways. also inhibition of dpp4 can alleviate atherosclerosis and heart failure. accordingly, one could hypothesize that high dpp4a may worsen myocardial i/r injury, causing poorer cardiovascular outcomes. however, no study has evaluated whether dpp4a is associated with adverse clinical outcomes in stemi patients.

Eligibility criteria:
inclusion criteria: * a diagnosis of stemi and needed pci exclusion criteria: * patients with cancer * patients who used dpp4 inhibitor * patients who used glp1 analogue
global study to assess the safety and effectiveness of edoxaban (du-176b) vs standard practice of dosing with warfarin in patients with atrial fibrillation

Conditions: Stroke; Atrial Fibrillation; Embolism

Summary: this study is to demonstrate the safety and efficacy profile, in two different dose regimens of edoxaban (du-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (see)), in individuals with atrial fibrillation. patients will be randomized to one of three treatment groups: high dose regimen, low dose regimen, \& warfarin. the expected duration of the study is 24 months.


Eligibility criteria:
inclusion criteria: * 21 years of age or older; male or female. * able to provide written informed consent. * history of documented af within the prior 12 months * a moderate to high risk of stroke, as defined by chads2 index score of at least 2 exclusion criteria: * transient atrial fibrillation secondary to other reversible disorders * subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve * subjects with any contraindication for anticoagulant agents; * subjects with conditions associated with high risk of bleeding or have known or suspected hereditary or acquired bleeding disorders * females of childbearing potential including the following: * females with a history of tubal-ligation * females less than 2 years post-menopausal

Keywords: systemic embolic events
epigenetic regulation in fibrous dysplasia of bone: mirdys study.

Conditions: Fibrous Dysplasia of Bone

Summary: fibrous dysplasia of bone is a rare congenital but non-hereditary disease caused by a post-zygotic activation mutation of the gnas gene. patients with fibrous dysplasia may present pain and bone complications (fractures, deformities..) related to their bone lesions. for undetermined reasons, severity and disease evolution may vary considerably from patient to patient. epigenetic regulation could then be involved, including micro ribonucleic acids (mirs). these small non-coding micro ribonucleic acids are involved in the regulation of major steps of cellular processes in different pathologies, in particular in bone diseases. however, micro ribonucleic acids have never been studied in fibrous dysplasia. the aim of this study is to identify micro ribonucleic acids significantly associated with the severity of fibrous dysplasia.


Eligibility criteria:
inclusion criteria: control population : * men and women, * 18 years-old and over, * consulting a rheumatologist or an orthopedist for arthrosis * have scheduled surgery for hip or knee replacement surgery or any intervention involving the lower limb or upper limb. patients with fibrous dysplasia: * men and women, * 18 years-old and over, * with a diagnosis of fibrous dysplasia previously established by a rheumatologist. exclusion criteria: * refusal to participate in the study * long- term corticosteroids treatment (\> 3 months) * treated osteoporosis * chronic inflammatory rheumatism (rheumatoid arthritis, psoriasic arthritis, spondyloarthropathy) * collagen disease (osteogenesis imperfecta...) * paget's disease, benign bone tumors * uncontrolled hypo/hyper-thyroidism, hypo/hyper-parathryoidism * severe renal impairment (gfr \< 30 ml/min/1.73m2) * cancer or bone metastases (current or in the past two years) * paget disease, benign bone tumor (osteoid osteoma, enchondroma ...) * malabsorptive disease (celiac disease, whipple's disease, intestinal bypass, short bowel syndrome) and inflammatory bowel disease * pregnant women or lactating * psychiatric disorders * difficulty in understanding french * not a beneficiary of french social security * patients protected by law
target effect-site concentration of remifentanil in transperineal prostate puncture

Conditions: Anesthesia, Intravenous

Summary: the research about the target effect-site concentration of remifentanil, inhibiting stress reaction of the perineal prostate puncture when dexmedetomidine being continuous pumping

patients who were scheduled to undergo transperineal prostate puncture and biopsy were recruited into our study. in all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target effect-site concentration of remifentanil was determined by sequential method. the first target effect-site concentration of remifentanil was set to 4.5ng/ml, the difference of adjacent target concentration was 0.5 ng/ml. cardiovascular positive reaction was defined as the changes of heart rate or systolic blood pressure was more than 15% compared with baseline values, or body movement observed. the adjacent target concentration difference was adjusted to 0.2 ng/ml after 3 negative and positive reaction cycles. if the first had a cardiovascular positive reaction, the target concentration of remifentanil increased by a concentration gradient. conversely, the target concentration of remifentanil decreased by a concentration gradient.

Eligibility criteria:
inclusion criteria: * patients of perineal prostate puncture exclusion criteria: * sinus bradycardia or atrioventricular block serious heart, brain, lung, liver, kidney, and metabolic disease allergy for dexmedetomidine or opioid

Keywords: dexmedetomidine remifentanil prostate puncture and biopsy
the interactive physical and cognitive exercise system

Conditions: Alzheimer Disease, Early Onset; MCI; Aging; Mild Cognitive Impairment; Neurocognitive Disorder; Cognitive Impairment; Cognitive Change

Summary: this study is intended to clarify the benefits to brain health and thinking processes that result from different forms of exercise. in particular, this study will investigate the possible benefits of physical exercise (such as pedaling an under-table stationary elliptical) or mental exercise (such as playing a videogame on a portable tablet), or combining these activities together (as in the ipaces™ exergame).


Eligibility criteria:
inclusion criteria: * co-residing older adults (e.g., spouses, partners, roommates, relatives) * both at least 50 years of age * normative/typical cognitive function or those with mild cognitive impairment (mci) or mild neurocognitive disorder (mncd) or early alzheimer's disease * adequate vision and dexterity for on-screen assessments * able to pedal an under-table elliptical * permission of primary care provider and cardiologist (if applicable) exclusion criteria: * history of seizure * parkinson's disease * significant dementia/memory loss

Keywords: exercise exergame
comparison of therapeutic effects of trigger point injection and twin nerve block in chronic myofascial pain patients

Conditions: Myofascial Pain - Dysfunction Syndrome of TMJ; Trigger Point Pain, Myofascial; Nerve Block

Summary: to see if there is there any difference in the treatment outcomes/results such as changes in pain intensity in patients with myofascial pain who have been treated with trigger point injections or twin block?

most treatment approaches for chronic myofascial pain are not evidence-based. studies are usually controversial. most are short-term, non-randomized. an essential limitation has been the lack of standardization of diagnosis. some studies do not differentiate between joint pain and muscle pain, which can significantly affect the outcome of the treatment provided. diagnostic criteria for temporomandibular disorders (dc/tmd) was recently published and validated. their protocol allows standardization of the assessment and diagnosis of patients with temporomandibular disorder, including myofascial pain. to the investigator's knowledge, no previous prospective, randomized study has been conducted demonstrating the treatment outcomes of either trigger point injections or twin block in patients with chronic myofascial pain.

Eligibility criteria:
inclusion criteria: * patients diagnosed with myofascial pain with referral based on the dc/tmd criteria * pain on the masseter and or temporalis muscles * pain present for at least 3 months exclusion criteria: * generalized muscle disorder such as fibromyalgia * subjects on chronic pain medication * subjects who are known to have hypersensitivity to the local anesthetics. * pregnant women. a pregnancy test will not be given before subject enrollment. women of childbearing ages will be asked verbally if they are pregnant. if they are unsure, then they will be excluded from the study. * subjects with cognitive problems e.g. alzheimer's disease.
yoga versus standard care for reducing fatigue in hispanic cancer survivors (yocas©®)

Conditions: Fatigue; Cancer

Summary: this is a phase ii 2-arm randomized controlled trial comparing yoga (yoga for cancer survivors, yocas©®) to standard care in reducing cancer-related fatigue in hispanic cancer survivors. survivors randomized to arm 1 will receive standard care and arm 2 will receive standard care plus a four-week yocas©® intervention where hispanic survivors attend yoga sessions together. investigators will acquire preliminary data on cancer-related fatigue, as well as, secondary data on other common side effects.

primary aim: to collect preliminary data comparing the effects of a yocas©® intervention to standard care on changes in cancer-related fatigue among hispanic cancer survivors immediately post-intervention. secondary aims: a) to collect preliminary data comparing the effects of a yocas©® intervention to standard care on changes in quality of life and physical functioning. outline: patients are randomized to 1 of 2 arms. arm 1 = participants undergo standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. participants in the control condition are offered the 4-week yocas©® program gratis after completing all study requirements. arm 2 = participants undergo the yocas©® intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.

Eligibility criteria:
inclusion criteria: * be at least 18 years of age * have a confirmed diagnosis of solid tumor or hematologic malignancy * have completed all chemotherapy, surgery, and/or radiation therapy within the last 2 years * have a score ≥4 on a 0-10 fatigue screening scale * be at least 18 years of age * self-identify as latino/a or hispanic * be able to read and understand english or spanish * be able to provide written informed consent * have the ability to attend 8 yoga sessions in-person exclusion criteria: * have contraindications to yoga participation per their primary physician or oncologist * have practiced yoga within the 3 months prior to enrolling in the study * be planning to start yoga on their own during the time they are enrolled in the study * have distant metastases
a study of entecavir in pediatric patients with chronic hepatitis b virus (hbv)-infection

Conditions: Hepatitis B, Chronic

Summary: the purpose of this clinical study is to determine the appropriate doses of entecavir to use in children and adolescents. safety, tolerability and efficacy will also be studied


Eligibility criteria:
inclusion criteria: * 2-18 years of age * group a: lamivudine naive (\ 12 weeks of lamivudine); group c: nucleoside/nucleotide experienced (\> 12 weeks of nucleoside/tide therapy) added as a country-specific protocol amendment (not all sites had group c). * hbv deoxyribonucleic acid (dna) ≥ 100000 copies/ml; ≥ 10000 copies for nucleoside/nucleotide experienced (group c) * detectable hepatitis b surface antigen (hbsag) for 24 weeks prior to screening * hepatitis b e antigen (hbeag) positive * compensated liver and renal function * elevated alanine aminotransferase (alt) at screening and during the 24 weeks prior to screening (for groups a and b) exclusion criteria: * coinfection with human immunodeficiency virus (hiv), hepatitis c virus (hcv), hepatitis d virus (hdv) * children who were breastfed while their mother received lamivudine, or children whose mothers received lamivudine during pregnancy
real world, open label, qol assessment of peanut immunotherapy ar101 in children and adolescents

Conditions: Peanut Allergy

Summary: to compare the hrqol of ar101 characterized oral desensitization immunotherapy (codit™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17 years.

this is a phase 3b, randomized, open label, european study of the hrqol of ar101 in combination with standard of care compared with standard of care alone in approximately 200 peanut-allergic subjects aged 4 to 17 years, inclusive.

Eligibility criteria:
key inclusion criteria: * age 4 through 17 years * history of physician diagnosed ige mediated peanut allergy with characteristic signs and symptoms * positive spt for peanut * positive serum ige to peanut * written informed consent from the subject's parent/guardian * written assent from the subject as appropriate * use of effective birth control by sexually active female subjects of childbearing potential key exclusion criteria: * uncertain clinical diagnosis of peanut allergy * history of severe or life threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening * severe persistent asthma or uncontrolled mild or moderate asthma * history of eosinophilic esophagitis, other eosinophilic gastrointestinal disease, severe gastroesophageal reflux disease, symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology * history of a mast cell disorder, including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema * history of cardiovascular disease, including uncontrolled or inadequately controlled hypertension * history of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen

Keywords: ar101 characterized peanut allergen (cpna) (characterized peanut allergen) oit peanut allergy allergy peanut-allergic children peanut-allergic adolescents desensitization quality of life oit (oral immunotherapy) codit (tm) characterized oral desensitization immunotherapy (tm)